Answers are grounded in this paper and cite their sources.
For DLBCL patients with non-GCB DLBCL and high Ki-67 expression, the survival benefit from R-CHOP therapy is limited.
No takes yet. Share an insight, caveat, or question.
Li et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: